As reported by the National Health Executive, advances in artificial intelligence are being harnessed to speed up the development of new medicines, as researchers in Liverpool begin work on a project designed to identify disease drivers and bring treatments to patients more quickly
The work will be delivered through a new partnership between the University of Liverpool and US based health technology company BPGbio, Inc., secured following a recent trade mission to the United States led by Liverpool City Region Mayor Steve Rotheram.
BPGbio specialises in AI driven medicine development and will work with researchers to further develop its NAi® Bayesian AI platform, which is designed to identify the biological drivers of disease. The collaboration will focus on improving the platform’s speed, scalability and real world application.
An interdisciplinary research team at the University of Liverpool will lead the project, applying the technology across drug discovery pipelines and clinical research settings to increase its practical impact.
Based in the University’s Civic HealthTech Innovation Zone, researchers will analyse a wide range of health data, including medical imaging, laboratory results, genetic and protein information, alongside patient outcomes.
By combining these datasets, the team aims to better understand cause and effect in disease processes, helping to identify new drug targets and shorten the path from research to treatment.
The project is expected to support advances in both drug discovery and precision medicine, enabling more targeted and effective therapies in the future.
Be the first to comment